Evidence map›Paper›PMID 30126369›Full record

ArticleBMC cancer2018

Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model.

Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kei Kawaguchi, Kentaro Igarashi, Kentaro Miyake, Masuyo Miyake, Yunfeng Li, Scott D Nelson, Sarah M Dry and 7 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Tasuku KiyunaAntiCancer Inc., San Diego, CA, USA.
Yasunori TomeDepartment of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. yash_toume@hotmail.com.
Takashi MurakamiAntiCancer Inc., San Diego, CA, USA.
Kei KawaguchiAntiCancer Inc., San Diego, CA, USA.
Kentaro IgarashiAntiCancer Inc., San Diego, CA, USA.
Kentaro MiyakeAntiCancer Inc., San Diego, CA, USA.
Masuyo MiyakeAntiCancer Inc., San Diego, CA, USA.
Yunfeng LiDepartment of Surgery, University of California, Los Angeles, CA, USA.
Scott D NelsonDepartment of Surgery, University of California, Los Angeles, CA, USA.
Sarah M DryDepartment of Surgery, University of California, Los Angeles, CA, USA.
Arun S SinghDivision of Hematology-Oncology, University of California, Los Angeles, CA, USA.
Tara A RussellDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Irmina ElliottDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Shree Ram SinghBasic Research Laboratory, National Cancer Institute, Frederick, MD, USA. singhshr@mail.nih.gov.ORCID http://orcid.org/0000-0001-6545-583X
Fuminori KanayaDepartment of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Fritz C EilberDivision of Surgical Oncology, University of California, Los Angeles, CA, USA. fceilber@mednet.ucla.edu.
Robert M HoffmanAntiCancer Inc., San Diego, CA, USA. all@anticancer.com.
University of California, Los Angeles · USUniversity of California San Diego · USUniversity of the Ryukyus · JPFrederick National Laboratory for Cancer Research · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
NCI NIH HHS P30 CA016042
6 · The paper itself

Abstract

backgroundPleomorphic liposarcoma (PLPS) is a rare, heterogeneous and an aggressive variant of liposarcoma. Therefore, individualized therapy is urgently needed. Our recent reports suggest that trabectedin (TRAB) is effective against several patient-derived orthotopic xenograft (PDOX) mouse models. Here, we compared the efficacy of first-line therapy, doxorubicin (DOX), and TRAB in a platelet-derived growth factor receptor-α (PDGFRA)-amplified PLPS.

methodsWe used a fresh sample of PLPS tumor derived from a 68-year-old male patient diagnosed with a recurrent PLPS. Subcutaneous implantation of tumor tissue was performed in a nude mouse. After three weeks of implantation, tumor tissues were isolated and cut into small pieces. To match the patient a PDGFRA-amplified PLPS PDOX was created in the biceps femoris of nude mice. Mice were randomized into three groups: Group 1 (G1), control (untreated); Group 2 (G2), DOX-treated; Group 3 (G3), TRAB-treated. Measurement was done twice a week for tumor width, length, and mouse body weight.

resultsThe PLPS PDOX showed resistance towards DOX. However, TRAB could arrest the PLPS (p < 0.05 compared to control; p < 0.05 compared to DOX) without any significant changes in body-weight.

conclusionsThe data presented here suggest that for the individual patient the PLPS PDOX model could specifically distinguish both effective and ineffective drugs. This is especially crucial for PLPS because effective first-line therapy is harder to establish if it is not individualized.

Indexed as

AgedAnimalsAntineoplastic Combined Chemotherapy ProtocolsDioxolesDoxorubicinDrug Resistance, NeoplasmHumansLiposarcomaMaleMiceNeoplasm Recurrence, LocalReceptor, Platelet-Derived Growth Factor alphaTetrahydroisoquinolinesTrabectedinXenograft Model Antitumor AssaysDioxolesDoxorubicinReceptor, Platelet-Derived Growth Factor alphaTetrahydroisoquinolinesTrabectedinLiposarcomaPatient-derived orthotopic xenograftPDGFRA amplificationPDOXPrecision medicineTrabectedin

Identifiers

PMID30126369
PMCPMC6102848
OpenAlexW2888260371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.